Document:

EX-10.3

 Exhibit 10.3 

EXECUTION 
 STOCK RESTRICTION
AGREEMENT 
 This STOCK RESTRICTION AGREEMENT (this “Agreement”) is
made as of November 16, 2018 (the “Effective Date”), by and between CytoDyn Inc., a Delaware corporation (“Company”), ProstaGene, LLC, a Delaware limited liability company (“ProstaGene”), and
Dr. Richard G. Pestell (the “Stockholder”). 
 RECITALS 

A.    The Stockholder was the founder and majority owner of ProstaGene, with approximately a 77.2% ownership interest, and
also owned certain intellectual property interests that he had previously licensed to ProstaGene. 
 B.    The Company,
certain of its predecessors and affiliates, ProstaGene and the Stockholder negotiated and entered into a Transaction Agreement, dated August 27, 2018 (the “ProstaGene Purchase Agreement”), to effect a holding company
reorganization and the purchase and sale of intellectual property and other assets of ProstaGene (including certain intellectual property interests licensed by the Executive to ProstaGene) for the aggregate stock consideration specified therein (the
“ProstaGene Acquisition”). 
 C.    Pursuant to the ProstaGene Purchase Agreement, the stock portion of
the consideration payable in the ProstaGene Acquisition consists of 27,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Stock Payment Shares”). 

C.    In connection with the ProstaGene Acquisition, the Stockholder is being appointed to the Company’s Board of
Directors (the “Board”) and is entering into an Employment Agreement (the “Employment Agreement”) as the Company’s Chief Medical Officer (collectively, the “Stockholder Appointments”). 

D.    In connection with the ProstaGene Acquisition and the Stockholder Appointments, the Stockholder and ProstaGene are
willing to enter into this Agreement and subject 8,342,000 Stock Payment Shares (collectively, the “Restricted Stock”) distributable to the Stockholder as a result of the ProstaGene Acquisition to the restrictions in this Agreement.

 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the
parties agree to the following between the parties as follows: 
 1.    REPURCHASE OPTION 

(a)    In the event the Stockholder’s employment under the Employment Agreement is terminated other than
(x) by the Company without Cause (as defined in the Employment Agreement), (y) by the Stockholder for Good Reason (as defined in the Employment Agreement) or (z) by reason of death or Disability (as defined in the Employment Agreement),
then the Company will have an irrevocable option (“Repurchase Option”), for a period of ninety (90) days after such termination, or such longer period as may be agreed to by the Company and the Stockholder, to repurchase from
the Stockholder or the Stockholder’s 

 
personal representative, as the case may be, at a purchase price of $0.001 per share of Preferred Stock or $0.001 per Conversion Share, as applicable (the “Option Price”), up to
but not exceeding the number of shares of Restricted Stock that have not vested in accordance with the provisions of Section 1(b) below as of such termination date. The Stockholder hereby acknowledges that the Company has no obligation,
either now or in the future, to repurchase any of the shares of Common Stock, whether vested or unvested, at any time. 

(b)    Vesting. One hundred percent (100%) of the Restricted Stock will initially be subject to the
Repurchase Option. The shares of the Restricted Stock will vest and be released from the Repurchase Option in three equal annual installments commencing on the date that is one year after the Effective Date, until all the Restricted Stock is
released from the Repurchase Option (provided in each case that the Stockholder remains an employee of the Company as of the date of such release). Notwithstanding the foregoing, the Repurchase Option will automatically lapse and all shares subject
to the Repurchase Option will immediately become fully vested and no longer subject to the Repurchase Option (i) on the effective date of a Change in Control of the Company, or (ii) if the Stockholder’s employment under the Employment
Agreement is terminated (x) by the Company without Cause (as defined in the Employment Agreement), (y) by the Stockholder for Good Reason (as defined in the Employment Agreement) or (z) by reason of death or Disability. 

(c)    Definitions. 

(i)    “Affiliate” shall have the meaning, with respect to a Person, a Person that directly or
indirectly Controls, or is Controlled by, or is under common Control with such Person. 
 (ii)    “Change
in Control” means (x) a change in ownership of the Company under clause (1) below or (y) a change in the ownership of a substantial portion of the assets of the Company under clause (2) below: 

(1)    Change in the Ownership of the Company. A change in the ownership of the Company shall occur on the
date that any one person, or more than one person acting as a group (as defined in clause (3) below), acquires ownership of capital stock of the Company that, together with capital stock held by such person or group, constitutes more than
50 percent of the total fair market value or total voting power of the capital stock of the Company. However, if any one person or more than one person acting as a group, is considered to own more than 50 percent of the total fair market
value or total voting power of the capital stock of the Company, the acquisition of additional capital stock by the same person or persons shall not be considered to be a change in the ownership of the Company. An increase in the percentage of
capital stock owned by any one person, or persons acting as a group, as a result of a transaction in which the Company acquires capital stock in the Company in exchange for property will be treated as an acquisition of stock for purposes of this
paragraph. 
 (2)    Change in the Ownership of a Substantial Portion of the Company’s Assets. A
change in the ownership of a substantial portion of the Company’s assets shall occur on the date that any one person, or more than one person acting as a group (as defined in clause (3) below), acquires (or has acquired during the 12-month period ending on the date of 

  
 -2- 

 
the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 80 percent of the total gross fair market value
of all of the assets of the Company immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without
regard to any liabilities associated with such assets. There is no Change in Control under this clause (2) when there is a transfer to an entity that is controlled by the shareholders of the Company immediately after the transfer, as provided
below in this clause (2). A transfer of assets by the Company is not treated as a change in the ownership of such assets if the assets are transferred to (a) a shareholder of the Company (immediately before the asset transfer) in exchange for
or with respect to its capital stock, (b) an entity, 50 percent or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (c) a person, or more than one person acting as a group, that owns,
directly or indirectly, 50 percent or more of the total value or voting power of all the outstanding capital stock of the Company, or (d) an entity, at least 50 percent of the total value or voting power of which is owned, directly or
indirectly, by a person described in clause (2)(c) of this paragraph. For purposes of this clause (2), a person’s status is determined immediately after the transfer of the assets. Notwithstanding anything in this clause (2) to the
contrary, in no event shall a license of (or other similar transfer of rights in) PRO 140 be a change in the ownership of a substantial portion of the Company’s assets. 

(3)    Persons Acting as a Group. For purposes of clauses (1) and (2) above, persons will not be
considered to be acting as a group solely because they purchase or own capital stock or purchase assets of the Company at the same time. However, persons will be considered to be acting as a group if they are owners of a corporation that enters into
a merger, consolidation, purchase or acquisition of assets or capital stock, or similar business transaction with the Company. If a person, including an entity, owns stock in both corporations that enter into a merger, consolidation, purchase or
acquisition of assets or capital stock, or similar transaction, such shareholder is considered to be acting as a group with other shareholders in a corporation only with respect to the ownership in that corporation before the transaction giving rise
to the change and not with respect to the ownership interest in the other corporation. For purposes of this paragraph, the term “corporation” shall have the meaning assigned such term under Treasury Regulation section 1.280G-1, Q&A-45. 
 (iii)    
“Control” shall have the meaning, as to any Person, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise (the terms
“Controlled by” and “under common Control with” shall have correlative meanings). 

(iv)     “Person” shall have the meaning: an individual, partnership, corporation, limited
liability company, trust, joint venture, unincorporated association, or other entity or association. 

2.    EXERCISE OF REPURCHASE OPTION. The Repurchase Option will
be exercised by written notice signed by an officer of the Company or by any assignee or assignees of the Company and delivered or mailed as provided in Section 11(a). Such notice will identify the number of shares of Restricted Stock to be
purchased and will notify the Stockholder of the time, place and date for settlement of such purchase, which will be scheduled by the Company within 

  
 -3- 

 
the term of the Repurchase Option set forth in Section 1(a) above. The Company will pay for any shares of Restricted Stock purchased pursuant to its Repurchase Option in cash. Upon delivery
of such notice and payment of the purchase price, the Company will become the legal and beneficial owner of the Restricted Stock being repurchased and all rights and interest in such shares, and the Company will have the right to transfer to its own
name the Restricted Stock being repurchased by the Company, without further action by the Stockholder or ProstaGene. 

3.    ADJUSTMENTS TO RESTRICTED STOCK. If, from time to time,
during the term of the Repurchase Option there is any change affecting the Company’s outstanding Common Stock as a class that is effected without the receipt of consideration by the Company (through merger, consolidation, reorganization,
reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, change in corporation structure or other transaction not involving the receipt of consideration by the Company), then
any and all new, substituted or additional securities or other property (including cash) to which the Stockholder is entitled by reason of the Stockholder’s ownership of Restricted Stock will be immediately subject to the Repurchase Option and
be included in the word “Restricted Stock” for all purposes of the Repurchase Option with the same force and effect as the shares of the Restricted Stock presently subject to the Repurchase Option, but only to the extent the
Restricted Stock is, at the time, covered by such Repurchase Option. While the total Option Price will remain the same after each such event, the Option Price per share of Restricted Stock upon exercise of the Repurchase Option will be appropriately
adjusted. 
 4.    ESCROW OF UNVESTED STOCK; PLEDGE
OF RESTRICTED STOCK. As soon as reasonably practicable after the Effective Date, the Company shall issue a stock certificate in the Stockholder’s name that corresponds to the Restricted Stock
(the “Certificate”), and shall hold such Certificate in escrow for the Stockholder’s benefit, properly endorsed for transfer, until such time as the Restricted Stock are forfeited to the Company or all restrictions thereon
lapse. The Company shall not be liable for any act it may do or fail to do with respect to the holding of the Certificate in escrow hereunder, provided it acts or fails to act in good faith and in accordance with this Agreement. 

5.    TERMINATION OF REPURCHASE OPTION. Sections 1, 2, 3, and 4
of this Agreement will terminate upon the exercise in full or expiration of the Repurchase Option, whichever occurs first. 

6.    RIGHTS OF THE STOCKHOLDER. Subject to the provisions of
Sections 4, 6, 8, and 9 of this Agreement, the Stockholder will exercise all rights and privileges of a stockholder of the Company with respect to the Restricted Stock deposited in escrow. The Stockholder will be deemed to be the holder for purposes
of receiving any dividends that may be paid with respect to such shares of Restricted Stock and for the purpose of exercising any voting rights relating to such shares of Restricted Stock, even if some or all of such shares of Restricted Stock have
not yet vested and been released from the Repurchase Option. 
 7.    LIMITATIONS ON
TRANSFER. In addition to any other limitation on transfer created by applicable securities laws, the Stockholder will not sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Restricted Stock
while the Restricted Stock is subject to the Repurchase Option. As a condition of this Agreement, the Stockholder may be required to execute a stock power in the form of Exhibit A hereto with respect to any shares issued pursuant to this
Agreement. 

  
 -4- 

 8.    RESTRICTIVE LEGENDS. All certificates
representing the Restricted Stock will have endorsed legends in substantially the following forms (in addition to any other legend which may be required by other agreements between the parties to this Agreement): 

(a)    “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AN OPTION SET FORTH IN A STOCK RESTRICTION
AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. ANY TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES SUBJECT TO SUCH OPTION IS
VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.” 
 (b)    “THE SHARES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN
OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 (c)    Any legend
required by appropriate blue sky officials. 
 The Company will remove or cause the removal of the foregoing legends as and to the extent of the lapse of
the applicable restrictions. 
 9.    REFUSAL TO TRANSFER. The Company will
not be required (a) to transfer on its books any shares of Restricted Stock of the Company which will have been transferred in violation of any of the provisions set forth in this Agreement, or (b) to treat as owner of such shares or to
accord the right to vote as such owner or to pay dividends to any transferee to whom such shares will have been so transferred. 

10.    SERVICE. Neither this Agreement nor any action taken hereunder shall be construed as giving the
Stockholder any right of continuing service with the Company. 
 11.    MISCELLANEOUS. 

(a)    Notices. All notices required or permitted hereunder will be in writing and will be deemed effectively
given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile or e-mail if sent during normal business hours of the recipient, and if not during normal business
hours of the recipient, then on the next business day, (iii) five (5) calendar days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) business day after deposit
with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications will be sent to the other party to this Agreement at such party’s address set forth on the signature page to
this Agreement, or at such other address as such party may designate by ten (10) days advance written notice to the other party to this Agreement. 

  
 -5- 

 (b)    Governing Law. This Agreement, and all matters
arising directly or indirectly herefrom, will be governed by and construed in accordance with the internal laws of the state of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law
of the state of Delaware. 
 (c)    Entire Agreement; Amendment. This Agreement (including the exhibits to
this Agreement) constitutes the entire agreement between the parties with respect to the subject matter of this Agreement and supersedes and merges all prior agreements or understandings, whether written or oral. This Agreement may not be amended,
modified or revoked, in whole or in part, except by an agreement in writing signed by each of the parties to this Agreement. 

(d)    Successors and Assigns. This Agreement will inure to the benefit of the successors and assigns of the
Company and, subject to the restrictions on transfer set forth in this Agreement, be binding upon ProstaGene, the Stockholder and the Stockholder’s successors and assigns. The Repurchase Option of the Company under this Agreement will be
assignable by the Company at any time or from time to time, in whole or in part. 
 (e)    Further
Execution. The parties agree to take all such further action(s) as may reasonably be necessary to carry out and consummate this Agreement as soon as practicable, and to take whatever steps may be necessary to obtain any governmental approval in
connection with or otherwise qualify the issuance of the securities that are the subject of this Agreement. 

(f)    Amendment. This Agreement may be amended or modified only by a written instrument executed by both
the Company and the Stockholder. 
 (g)    Severability. If one or more provisions of this Agreement are
held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such
provision will be excluded from this Agreement, (ii) the balance of the Agreement will be interpreted as if such provision were so excluded and (iii) the balance of the Agreement will be enforceable in accordance with its terms. 

(h)    Counterparts. This Agreement may be executed in two or more counterparts, including facsimile
counterparts, each of which will be deemed an original and all of which together will constitute one instrument. 
 [Signature Page
Follows] 

  
 -6- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date
first written above. 
  

			
	    CYTODYN INC.
		
	    By:	 	 /s/ Michael D. Mulholland

	    Name:	 	Michael D. Mulholland
	    Title:	 	Chief Financial Officer
	
	    STOCKHOLDER
	
	     /s/ Richard G.
Pestell

	    Name:	 	Richard G. Pestell

  

			
	ACKNOWLEDGED AND AGREED:
	
	PROSTAGENE, LLC

			
		
	By:	 	 /s/ Richard Pestell

	Name:	 	Richard Pestell
	Title:	 	Chief Executive Officer

 ATTACHMENTS: 

Exhibit A – Stock Power 

  
 Signature Page to
Stock Restriction Agreement 

 Exhibit A-1 

STOCK POWER 

FOR VALUE RECEIVED, Richard G. Pestell , hereby sells, assigns, and transfers unto CytoDyn Inc.
                 shares of Series C convertible preferred stock, par value $0.001 per share, of CytoDyn Inc. (the “Company”), issued pursuant to, and
subject to the terms of, that certain Stock Restriction Agreement by and between the Company and Richard G. Pestell, dated                    ,
20    , standing in his/her name on the books of said corporation represented by Certificate No.      herewith, and does hereby irrevocably constitute and appoint
                     as his/her attorney to transfer the said stock on the books of said corporation with full power of substitution in the premises.

  

			
	Dated:	 	                    
		 	

  

			
		 	 /s/ Richard G. Pestell

		 	Richard G. Pestell

 [INSTRUCTION: Please do not fill in any blanks other than the signature line.
The purpose of this assignment is to enable the Company to exercise its Repurchase Option set forth in the Agreement without requiring additional signatures on the part of the Stockholder.] 

 Exhibit A-2 

STOCK POWER 

FOR VALUE RECEIVED, Richard G. Pestell , hereby sells, assigns, and transfers unto CytoDyn
Inc.                 shares of common stock, par value $0.001 per share, of CytoDyn Inc. (the “Company”), issued pursuant to, and subject to the terms
of, that certain Stock Restriction Agreement by and between the Company and Richard G. Pestell, dated                     ,
20    , standing in his/her name on the books of said corporation represented by Certificate No.      herewith, and does hereby irrevocably constitute and appoint
                     as his/her attorney to transfer the said stock on the books of said corporation with full power of substitution in the premises.

  

			
	Dated:	 	                    
		 	

  

			
		 	 /s/ Richard G. Pestell

		 	Richard G. Pestell

 [INSTRUCTION: Please do not fill in any blanks other than the signature line.
The purpose of this assignment is to enable the Company to exercise its Repurchase Option set forth in the Agreement without requiring additional signatures on the part of the Stockholder.]EX-10.4

 Exhibit 10.4 

EXECUTION 
 CONFIDENTIAL
INFORMATION, INVENTIONS 
 AND NONCOMPETITION AGREEMENT 

This CONFIDENTIAL INFORMATION, INVENTIONS AND NONCOMPETITION AGREEMENT (this “Agreement”), dated as of November 16, 2018
(the “Effective Date”), is by and among CYTODYN INC., a Delaware corporation (“HoldCo”), CYTODYN OPERATIONS INC., a Delaware corporation and wholly owned subsidiary of HoldCo (“OpCo” and together
with HoldCo, the “Company”), and me, Dr. Richard G. Pestell. 
 W I T N E S S E T H: 

WHEREAS, I am the founder and principal member of ProstaGene, LLC, a Delaware limited liability company (“ProstaGene”), with
approximately a 77.2% ownership interest, and I also own certain intellectual property interests that I have previously licensed to ProstaGene; 

WHEREAS, the Company, certain of its predecessors and affiliates, ProstaGene and I have negotiated and entered into a Transaction Agreement,
dated August 27, 2018 (the “ProstaGene Purchase Agreement”), to effect a holding company reorganization and the purchase and sale of intellectual property and other assets of ProstaGene (including certain intellectual property
interests licensed by me to ProstaGene) for the aggregate stock consideration specified therein (the “ProstaGene Acquisition”); 

WHEREAS, in connection with the ProstaGene Acquisition, I am being appointed to the Company’s Board of Directors and am entering into an
employment agreement as the Company’s Chief Medical Officer (the “Employment Agreement”); and 
 WHEREAS, in
connection with and in consideration of the foregoing, I have agreed to execute and be bound by the terms of this Agreement. 
 NOW,
THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound hereby, I
hereby agree with the Company as follows: 
  

	1.	 Representations and Warranties 

1.1    No Conflict with any Other Agreement or Obligation. I represent and warrant that, other than as set
forth on Schedule 1.1, I am not bound by any agreement or arrangement with or duty to any other person that would conflict with this Agreement. I shall not disclose to the Company or induce the Company to use any
proprietary, trade secret or confidential information or material belonging to others. 
  

	2.	 Confidential Information 

2.1    Definition of Confidential Information. “Confidential Information” means all of the
trade secrets, know-how, ideas, business plans, pricing information, the identity of and any information concerning customers or suppliers, computer programs (whether in source code or

 
object code), procedures, processes, materials (including biological materials), data, nonpublic regulatory information, experimental protocols and results, nonpublic algorithms (including gene
signature algorithms), strategies, methods, systems, designs, discoveries, inventions, production methods and sources, marketing and sales information, information received from others that the Company is obligated to treat as confidential or
proprietary, information relating to the Company’s corporate finance and liquidity transactions, and any other technical, operating, financial and other business information relating to the Company, its business, potential business, operations
or finances, or the business of the Company’s affiliates or customers, of which I may have acquired or developed knowledge or of which I may in the future acquire or develop knowledge of during my work for the Company, or from my colleagues
while working for the Company. Confidential Information does not include any of the foregoing that is or becomes available to the public other than as a result of a disclosure by me in breach of this Agreement. 

2.2    Protection of Confidential Information. I will use the Confidential Information only in the
performance of my duties for the Company. I will not disclose the Confidential Information, directly or indirectly, at any time during or after my employment by the Company except to persons authorized by the Company to receive this information. I
will not use the Confidential Information, directly or indirectly, at any time during or after my employment by the Company, for my personal benefit, for the benefit of any other person or entity, or in any manner adverse to the interests of the
Company. I will take all action reasonably necessary to protect the Confidential Information from being disclosed to anyone other than persons authorized by the Company. Notwithstanding the foregoing or anything else contained herein to the
contrary, this Agreement shall not preclude me from disclosing Confidential Information to a governmental body or agency or to a court if and to the extent that a restriction on such disclosure would limit me from exercising any protected right
afforded to me under applicable law, including the ability to receive an award for information provided to the Securities Exchange Commission or any other governmental body. 

2.3    Return of Confidential Information. When my employment by the Company terminates or at any time upon
demand, I will immediately return or destroy all materials (including without limitation, written or printed documents, email and computer disks or tapes, whether machine or user readable, computer memory, and other information reduced to any
recorded format or medium) containing, summarizing, abstracting or in any way relating to the Confidential Information. At the time I return these materials I will acknowledge to the Company, in writing and under oath, in the form attached as
Exhibit A, that I have complied with the terms of this Agreement. I further agree that any electronic accounts I open, handle or become involved with on the Company’s behalf constitute Company property. I will provide
all access codes, passcodes, and administrator rights to the Company at any time during or after my employment on demand. 

2.4    Defend Trade Secrets Act Notice. I acknowledge receipt of notice of the following immunities under 18
USC Section 1833(b): 
 (a)    An individual shall not be held criminally or civilly liable under any U.S. federal
or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney and (B)

  
 2 

 
solely for the purpose of reporting or investigating a suspected violation of law or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is
made under seal. 
 (b)    In addition, an individual who files a lawsuit for retaliation by an employer for reporting a
suspected violation of law may disclose the employer’s trade secrets to his or her attorney and use the trade secret information in the court proceeding if the individual: (i) files any document containing the trade secret under seal and
(ii) does not disclose the trade secret, except pursuant to court order. 
  

	3.	 Inventions 

3.1    Definition of Inventions. The term “Inventions” means: 

(a)    contributions and inventions, discoveries, creations, developments, improvements, works of authorship and ideas
(whether or not they are patentable or copyrightable) of any kind that are conceived, created, developed or reduced to practice by me, alone or with others, while I am employed by the Company that are either: (i) conceived or reduced to
practice while working at the Company or with the use of the Company resources, facilities or materials, (ii) relate to the Company’s business or actual or demonstrably anticipated research or development, or (iii) result from any
work performed by me for the Company; and 
 (b)    any and all patents, patent applications, copyrights, trade secrets,
trademarks, domain names and other intellectual property rights, worldwide, with respect to any of the foregoing. 

(c)    The term “Inventions” specifically excludes any inventions that I develop entirely on my own time without
using any Company equipment, supplies, facilities or trade secret information, except for those inventions that: (a) relate to the Company’s business or actual or demonstrably anticipated research or development; or (b) result
from any work performed by me for the Company. The term “Inventions” also specifically excludes any invention that is subject to the invention policy of Baruch S. Blumberg Institute (“Blumberg”) in effect on
January 1, 2017, except to the extent assigned to the Company under the Intellectual Property Agreement among the Company (as the assignee of ProstaGene), Blumberg and me effective January 1, 2017. 

3.2    All Inventions are Exclusively the Property of the Company. 

(a)    I will promptly disclose all Inventions made or conceived, reduced to practice or learned by me, either alone or
jointly with others, in full detail, to the Chief Financial Officer and Chief Executive Officer of the Company using the form attached as Exhibit B. I will not disclose any Invention to anyone other than persons authorized
by the Company, without the Company’s express prior written instruction to do so. 
 (b)    All Inventions will be
deemed “work made for hire” as that term is used in the U.S. Copyright Act, and belong solely to the Company from conception. I hereby expressly disclaim all interest in all Inventions. To the extent that title to any Invention or any
materials comprising or including any Invention is found not be a “work made for hire” as a matter of law, 

  
 3 

 
I hereby irrevocably assign to the Company all of my right, title and interest to that Invention. At any time during or after my employment by the Company that the Company requests, I will sign
whatever written documents of assignment are necessary to formally evidence my irrevocable assignment to the Company of any Invention. 

(c)    At all times during or after my employment by the Company I will assist the Company in obtaining, maintaining and
renewing patent, copyright, trademark and other appropriate protection for any Invention, in the United States and in any other country, at the Company’s expense. 

(d)    During the term of my employment with the Company, to the extent that I, as the principal investigator at Blumberg
or any other applicable research or academic institution (each, an “Applicable Institution”), make an invention disclosure or create any other licensable or transferable intellectual property (the “Subject IP”), (i)
to the extent I have a right or opportunity to consent to the licensing or transfer of the Subject IP, I will notify the Company, will use best efforts to cause the owner of the Subject IP to negotiate with the Company for an exclusive or non-exclusive license agreement or option agreement for the Subject IP and will not, without the Company’s consent, consent to a license or transfer of the Subject IP to anyone other than the Company or its
affiliates, unless and until the Company declines to enter into or terminates such negotiations without entering into a definitive license agreement or option agreement for the Subject IP; and (ii) to the extent that I have a right or
opportunity to own any Subject IP, I will notify the Company and use best efforts, subject to the Company’s prior written consent and on the Company’s behalf, to pursue ownership of such inventions and transfer such ownership rights to the
Company; in the case of each of clauses (i) and (ii) above, for no additional consideration payable to me directly or indirectly by the Company, other than under the intellectual property policy of any Applicable Institution. 

(e)    Other than as set forth in Schedule 3.2, I am not aware of any prior, ongoing or
anticipated studies that would fall within the scope of the covenants set forth in Section 3.2(d). During the term of my employment with the Company, with respect to any research that relates to any Company Business (as
defined below), I will provide advance written notice including the proposed research plan (the “Research Plan”) to the Company’s Board of Directors. The Company shall have the opportunity to direct the Research Plan to be
conducted under the Master Sponsored Research Agreement, dated as of January 1, 2017, between the Company (as the assignee of ProstaGene) and Blumberg, or under a similar sponsored research program with another Applicable Institution, or
through the Company’s own private research facilities. If the Company’s Board of Directors reasonably determines that the Research Plan may conflict with the Company’s clinical development strategies relating to any Company Business,
I will revise the Research Plan to address any such concerns prior to initiating any such research through an Applicable Institution. 

4.    Non-Compete. In order to protect the legitimate business interests of the
Company and in consideration of the compensation I am receiving in the ProstaGene Transaction and as Chief Medical Officer and a director of the Company, and of the Company’s willingness to provide to me access to its Confidential Information,
I agree that during the period beginning on the closing of the ProstaGene Transaction (the “Closing Date”) and ending on the later of (a) five (5) years after the Closing Date or (b) one (1) year following the
termination of my employment for any 

  
 4 

 
reason (the “Restricted Period”), I will not directly or indirectly, whether as owner, sole proprietor, partner, shareholder, director, member, consultant, agent, founder, co-venture partner or otherwise, engage, invest or otherwise participate or provide any services, research or consultation, to a Competing Business, except to the extent of any Permitted Activities that are or (to
the extent the Employment Agreement has previously been terminated) would have been permissible under Section 2.4 of the Employment Agreement. A “Competing Business” is any business that engages, plans to engage or, within the
then most recent one-year period prior to the date of termination, was engaged in any of the following (collectively, the “Company Business”): (x) research or development relating to CCR5
receptor function, including the study of anti-CCR5 agents alone or together with non-CCR5 agents, in the fields of oncology or immunology for diagnostic, prognostic or
therapeutic application; or (y) any other business that the Company is conducting or demonstrably planning to conduct as of such date. I further acknowledge that the Company’s business is international in scope and therefore the
restrictions herein shall apply anywhere in the world; if, however, a court of competent jurisdiction were to determine that this geographic scope is overbroad, the restriction shall be limited to the United States; and if, however, a court of
competent jurisdiction were to determine that this geographic scope is overbroad, the restriction shall be limited to any state where the Company does business (the “Restricted Area”). 

5.    Non-Solicitation. To protect the legitimate business interests of the Company
and in consideration of the compensation I am receiving in the ProstaGene Transaction and as Chief Medical Officer and a director of the Company, and of the Company’s willingness to provide to me access to its Confidential Information, I agree
that during the Restricted Period and in the Restricted Area, I will not directly or indirectly, whether as owner, sole proprietor, partner, shareholder, director, member, employee, consultant, agent, founder,
co-venture partner or otherwise: 
 (a)    solicit or interfere with any of the
Company’s customers, clients, Prospective Customers or Clients (defined below), members, business partners or suppliers. A “Prospective Customer or Client” is any person or entity solicited by the Company at any time during the
period of my employment, with whom or which I had contact, or about whom or which I received Confidential Information; or 

(b)    solicit, recruit, hire, engage, or refer (or assist any third party in soliciting, recruiting, hiring, engaging or
referring) any person or entity who or which either is, or during the twelve (12) months immediately preceding the termination of my employment was, an employee, agent, consultant or independent contractor of the Company. 

 

	6.	 Miscellaneous 

6.1    Interpretation and Scope of this Agreement. Each provision of this Agreement shall be interpreted on
its own. If any provision is held to be unenforceable as written, it shall be enforced to the fullest extent permitted under applicable law. In the event that one or more of the provisions contained in this Agreement shall for any reason be held
unenforceable in any respect under the law of any state of the United States or the United States, then it shall (a) be enforced to the fullest extent permitted under applicable law, and (b) such unenforceability shall not affect any other
provision of this Agreement, but this Agreement shall then be construed as if such unenforceable portion(s) had never been contained herein. 

  
 5 

 6.2    Remedies. I understand and agree that if I breach
or threaten to breach any of the provisions of this Agreement the Company would suffer immediate and irreparable harm and that monetary damages would be an inadequate remedy. I agree that, in the event of my breach or threatened breach of any of the
provisions of this Agreement, the Company shall have the right to relief from a court to restrain me (on a temporary, preliminary and permanent basis) from using or disclosing Company Confidential Information or Inventions or otherwise violating any
of the provisions of this Agreement, and that any such restraint shall be in addition to (and not instead of) any and all other remedies to which the Company shall be entitled, including money damages. The Company shall not be required to post a
bond or other security to secure against an imprudently granted injunction (again, whether temporary, preliminary or permanent). 

6.3    Governing Law; Jury Waiver; Consent to Jurisdiction. I acknowledge that the governing documents
surrounding the ProstaGene Acquisition are governed by Delaware law. Accordingly, this Agreement (together with any and all modifications, extensions and amendments of it) and any and all matters arising directly or indirectly herefrom shall be
governed by and construed and enforced in accordance with the internal laws of the State of Delaware applicable to agreements made and to be performed entirely in such state, without giving effect to the conflict or choice of law principles thereof.
For all matters arising directly or indirectly from this Agreement (“Agreement Matters”), I hereby (i) irrevocably consent and submit to the sole exclusive jurisdiction of the state and federal courts of the State of Delaware
and the parties hereto hereby irrevocably submit to the exclusive jurisdiction of any such courts in connection with any legal action, lawsuit, arbitration, mediation, or other legal or quasi legal proceeding (“Proceeding”) directly
or indirectly arising out of or relating to any Agreement Matter; provided that a party to this Agreement shall be entitled to enforce an order or judgment of any such court in any United States or foreign court having jurisdiction
over the other party, (ii) irrevocably waive, to the fullest extent permitted by law, any objection that I may now or later have to the laying of the venue of any such Proceeding in any such court or that any such Proceeding which is brought in
any such court has been brought in an inconvenient forum, (iii) irrevocably waive, to the fullest extent permitted by law, any immunity from jurisdiction of any such court or from any legal process therein, (iv) irrevocably waive, to the
fullest extent permitted by law, any right to a trial by jury in connection with a Proceeding, (v) covenant that I will not, directly or indirectly, commence any Proceeding other than in such courts, and (vi) agree that service of any
summons, complaint, notice or other process relating to such Proceeding may be effected in the manner provided for the giving of notice as set forth in this Agreement. 

6.4    Entire Agreement; Amendments and Waivers. This Agreement represents the entire understanding and
agreement among the parties hereto with respect to the subject matter hereof and can be amended, supplemented, or changed and any provision hereof can be waived, only by written instrument signed by the party against whom enforcement of any such
amendment, supplement, change or waiver is sought. 

  
 6 

 6.5    Survival. I acknowledge and agree that the
restrictions that are set forth in this Agreement and the location and period of time for which such restrictions apply are reasonable and necessary to protect the Company’s legitimate business interests and shall survive the expiration or
termination of this Agreement as well as the termination of my employment for any reason. I further acknowledge that the restrictions contained in this Agreement will not prevent me from earning a livelihood during the applicable period of
restriction. 
 6.6    Captions. The captions and section headings in this Agreement are included solely
for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement. 

6.7    Counterparts; Binding Effect. This Agreement may be executed in counterparts, each of which shall be
deemed an original agreement, but all of which together shall constitute one and the same agreement. Except as otherwise expressly provided herein, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and permitted assigns, including, without limitation, a purchaser of all or substantially all of the assets of the Company or any of its affiliates. Signatures delivered by facsimile (including without limitation by
“pdf”) shall be deemed effective for all purposes. 
 6.8    Notices. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent
during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day
after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications to me shall be sent to the respective parties at their address as set forth on the signature page
of this Agreement, or in the Company’s records, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section and all notices
to the Company shall be provided to the Company’s headquarters, attention CEO, with a copy which, itself, shall not constitute notice, to Michael J. Lerner, Esq., Lowenstein Sandler LLP, 1251 Avenue of the Americas, New York New York 10020.

 [Signature Page Follows] 

  
 7 

 By signing this Agreement below, (1) I agree to be bound by each of its terms, (2) I
acknowledge that I have read and understand this Agreement and the important restrictions it imposes upon me, and (3) I represent and warrant to the Company that I have had ample and reasonable opportunity to consult with legal counsel of my
own choosing to review this Agreement and understand its terms including that it places significant restrictions on me. 
  

											
	WITNESS:	 		 		 	EMPLOYEE:	 		 	

											
						
	By:	 	  
	 		 	By:	 	 /s/ Richard G. Pestell
	 	

											
						
	Name:	 	  
	 		 	Name:	 	 Dr. Richard G. Pestell
	 	

											
						
		 		 		 	Address:	 	 901 North Penn Street, Apt. R1902

Philadelphia, PA 19123
	 	

											
						
	Date:	 	  
	 		 	Date:	 	 November 15, 2018
	 	

											
					
	Accepted by Company:	 		 		 		 	
					
	CytoDyn Operations Inc.	 		 		 		 	

											
						
	By:	 	 /s/ Michael D. Mulholland
	 		 		 		 	

											
						
	Name:	 	 Michael D. Mulholland
	 		 		 		 	

											
						
	Title:	 	 Treasurer, Corporate Secretary and Chief Financial Officer
	 		 		 		 	

											
						
	Date:	 	 16 November 2018
	 		 		 		 	

  
 [Confidentiality,
Inventions and Noncompetition Agreement] 

 SCHEDULE 1.1 

Conflicts 
 Invention Policy of Baruch S.
Blumberg Institute 

 SCHEDULE 1.1 

Ongoing Studies 
  

											
	 Grant
	 	 PI
	 	 Date
	 	 Subject
	 	Annual	 	Total Grant
	Falk Trust	 	Pestell	 	9/1/11 to 11/30/18	 	Targeting CCR5 for cancer treatment (includes clinical trial)	 	$500,000/yr	 	$1,500,000
						
	Breast Cancer Research Program, Breakthrough	 	Pestell	 	7/1/18 to 6/30/21	 	Novel mechanisms governing human breast cancer chromosomal instability	 	$390,000/yr	 	$1,170,000

 EXHIBIT A 

Form of Acknowledgment 

My employment by CytoDyn Operations Inc. and CytoDyn Inc. (collectively, the “Company”) is now terminated. I have reviewed my
Confidential Information, Inventions and Noncompetition Agreement with the Company, dated August     , 2018 (the “Agreement”), and I swear, under oath, that: 

 

	 	•	 	 I have complied and will continue to comply with all of the provisions of the Agreement. 

 

	 	•	 	 I understand that all of the Company’s materials (including without limitation, written or printed
documents, email and computer disks or tapes, whether machine or user readable, computer memory, and other information reduced to any recorded format or medium), whether or not they contain Confidential Information (as that phrase is defined in the
Agreement), are and remain the property of the Company. I have delivered to authorized Company personnel, or have destroyed, all of those documents and all other Company materials in my possession. 

 

	 	•	 	 I acknowledge and agree that the restrictions that are set forth in the Agreement with respect to the
Confidential Information shall survive the expiration or termination of the Agreement as well as the termination of my employment with the Company for any reason. 

 

	
	  

	Signature
	
	  

	Name (please print clearly)
	
	  

	
	  

	Address

 STATE OF
                            ) 

                          
                      ) ss.: 
 COUNTY OF
                        ) 

BE IT REMEMBERED, that on this          day of
            ,         , before me, the subscriber, a notary public of the State of
                    , personally appeared
                                , who being by me duly sworn on his oath, deposed and
made proof to my satisfaction that (s)he is the person named in the within instrument, to whom I first made known the contents thereof, and thereupon (s)he acknowledged that (s)he signed, sealed and delivered the same as his/her voluntary act and
deed for the uses and purposes therein expressed. 
  

									
		 		 		 	  
	  	
		 	[SEAL]	 		 	Notary Public	  	

 EXHIBIT B 

Invention Disclosure Form 

 INVENTION DISCLOSURE FORM 

INSTRUCTIONS: Use this form for submitting an initial disclosure of your invention. If necessary, please attach and number any additional pages. After
completing and signing this form, immediately forward it to Michael D. Mulholland, as Chief Financial Officer, and Nader Z. Pourhassan, Ph.D., as Chief Executive Officer. 

CytoDyn Operations Inc. and CytoDyn Inc. (collectively, “CytoDyn”) will review all complete Invention Disclosure Forms as they are received from
employees and consultants of CytoDyn. Invention Disclosure Forms are reviewed for patentability and for commercial potential. All information on the form must be completed in order for CytoDyn to perform its review. Typically, CytoDyn files a
provisional patent application on any invention that may be patentable and commercially valuable. 
 The purpose of this form is to notify CytoDyn of your
potential invention and any relevant related information. The form also serves to establish a legal record of the date of invention conception. This form should be submitted to the Chief Financial Officer and the Chief Executive Officer when
something new and useful has been conceived, or when unusual, unexpected, or unobvious research results have been achieved and can be used. 
  

	
	  

	
	I. Descriptive title of the invention:
	
	  

	
	  

	
	II. Individual Submitting This Form
	
	  

	Full Name
	
	  

	Home Address (Street)
	
	  

	City, County, State, Zip
	
	  

	Work Phone
	
	  

	Citizenship
	
	  

	Signature
	
	  

	Date

  
 PAGE 1
OF 7 
 This information is confidential and proprietary to CytoDyn Operations Inc. and CytoDyn Inc. and is not intended for
public dissemination. 

					
	 III. Other Individuals Who Assisted In Developing This Invention

 

	  
	  	  
	  	  

	Full Name	  	Full Name	  	Full Name
			
	  
	  	  
	  	  

	Home Address (Street)	  	Home Address (Street)	  	Home Address (Street)
			
	  
	  	  
	  	  

	City, County, State, Zip	  	City, County, State, Zip	  	City, County, State, Zip
			
	  
	  	  
	  	  

	Work Phone	  	Work Phone	  	Work Phone
			
	  
	  	  
	  	  

	Citizenship	  	Citizenship	  	Citizenship
			
	  
	  	  
	  	  

	Signature	  	Signature	  	Signature
			
	  
	  	  
	  	  

	Date	  	Date	  	Date

  

	
	IV. Planned or Actual Use of the Invention:

	
	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

  
 PAGE 2
OF 7 
 This information is confidential and proprietary to CytoDyn Operations Inc. and CytoDyn Inc. and is not intended for
public dissemination. 

					
		  	(yes)	  	(no)
			
	V. Disclosure of the Invention:	  		  	
			
	 1.  With respect to this invention:
	  		  	
			
	 A. Have any discussions or other contacts been made with potential purchasers?
	  	(    )	  	(    )
			
	 B. Has it been sold or offered for sale?
	  	(    )	  	(    )
			
	 C. If it pertains to a process, have any steps been taken to employ the process
commercially?
	  	(    )	  	(    )
			
	 D. Has it been described in a printed publication?
	  	(    )	  	(    )
			
	 E.  Has it been disclosed in a talk or a paper presented at a public
meeting?
	  	(    )	  	(    )
			
	 F.  Has it been otherwise disclosed to vendors or customers?
	  	(    )	  	(    )
			
	 G. If not, is any such use, sale, publication or disclosure now
contemplated?
	  	(    )	  	(    )
			
	 H. Has it been reduced to practice (i.e., made, carried out, or built and tested) or has a
model or prototype been built?
	  	(    )	  	(    )
			
	 I.   Is there any agreement that deals with rights in this invention or
ownership of this invention?
	  	(    )	  	(    )
			
	 2.  If any answer to any part of question 1 is “YES,” please indicate
earliest dates, and give the surrounding circumstances (attach additional sheet(s) if necessary):
	  		  	
	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

  
 PAGE 3
OF 7 
 This information is confidential and proprietary to CytoDyn Operations Inc. and CytoDyn Inc. and is not intended for
public dissemination. 

	
	VI. Description:
	
	Please add any additional sheets and drawings necessary to describe the invention.
	
	 1.  Summary of the Invention:

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	 2.  What problem is solved?

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

  
 PAGE 4
OF 7 
 This information is confidential and proprietary to CytoDyn Operations Inc. and CytoDyn Inc. and is not intended for
public dissemination. 

	
	 3.  Describe any similar system(s) that you are aware of and the advantages of the
invention over these other system(s) or method(s).

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	 4.  Technical description of the invention (refer to drawings with reference
numerals).

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

  
 PAGE 5
OF 7 
 This information is confidential and proprietary to CytoDyn Operations Inc. and CytoDyn Inc. and is not intended for
public dissemination. 

	
	 5.  What aspects of the Invention can be varied or altered, and yet still accomplish
the end result or object of the invention?

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	 6.  Supporting documentation as to when and where the invention was first conceived.
Please list any relevant written or pictorial material (notebook number and page, file reports or drawings, etc.).

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

	
	  

  
 PAGE 6
OF 7 
 This information is confidential and proprietary to CytoDyn Operations Inc. and CytoDyn Inc. and is not intended for
public dissemination. 

											
	Invention Witnessed and Understood By:	  		 	Evaluated and Understood By:	 	

											
						
	Signature:	 	  
	  		 	Signature:	 	  
	 	

											
						
	Printed Name:	 	  
	  		 	Printed Name:	 	  
	 	

											
						
	Title:	 	  
	  		 	Title:	 	  
	 	

											
						
	Date:	 	  
	  		 	Date:	 	  
	 	

  
 PAGE 7
OF 7 
 This information is confidential and proprietary to CytoDyn Operations Inc. and CytoDyn Inc. and is not intended for
public dissemination.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]